ArticleOncotarget2017
Gene-modified NK-92MI cells expressing a chimeric CD16-BB-ζ or CD64-BB-ζ receptor exhibit enhanced cancer-killing ability in combination with therapeutic antibody.
Ying Chen et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
30 papers cite it
this papercites it